Omneity® Pellets
All-In-One Vitamin & Mineral Pellet
Topic:Remission
Remission in horses refers to the period during which the symptoms of a disease or condition are reduced or disappear entirely. This phase can occur naturally or as a result of treatment, and it is an important aspect of managing chronic conditions in equine health. Remission is commonly discussed in the context of diseases such as equine metabolic syndrome, laminitis, and inflammatory conditions. Monitoring remission involves regular veterinary assessments to evaluate the horse's clinical signs and overall health status. This page compiles peer-reviewed research studies and scholarly articles that explore the mechanisms, duration, and management strategies associated with remission in various equine diseases.
Breath characteristics and adventitious lung sounds in healthy and asthmatic horses. Standard thoracic auscultation suffers from limitations, and no systematic analysis of breath sounds in asthmatic horses exists. Objective: First, characterize breath sounds in horses recorded using a novel digital auscultation device (DAD). Second, use DAD to compare breath variables and occurrence of adventitious sounds in healthy and asthmatic horses. Methods: Twelve healthy control horses (ctl), 12 horses with mild to moderate asthma (mEA), 10 horses with severe asthma (sEA) (5 in remission [sEA-], and 5 in exacerbation [sEA+]). Methods: Prospective multicenter case-control study. Horses w...
Efficacy and Safety of Subcutaneous Allergen-Specific Immuno-Therapy in Horses with Allergic Cutaneous and Respiratory Diseases-A Systematic Review. Allergen-specific immunotherapy (AIT) is the only current intervention that has the ability to modify the immune response toward a tolerogenic state. This study aimed to assess the efficacy and safety of AIT in horses with allergic diseases in a systematic manner. Three databases were searched to identify articles reporting clinical outcomes and adverse events associated with AIT. The articles were evaluated for beneficial responses to AIT, defined as a ≥50% reduction in clinical signs, and clinical remission. Horses with respiratory diseases, urticaria, and pruritic dermatitis receiving ins...
Topical treatment of equine sarcoids with imiquimod 5% cream or Sanguinaria canadensis and zinc chloride – an open prospective study. Equine sarcoids are the most prevalent skin neoplasm in horses worldwide. Although several treatments are available, none are consistently effective and recurrence is common. Objective: To evaluate the efficacy and safety of topical imiquimod 5% cream and Sanguinaria canadensis + zinc chloride for treatment of equine sarcoids and investigate possible systemic effects on distant untreated sarcoids. Unassigned: Twenty-five client-owned horses with a total of 164 tumours were included in the study. Fifty-seven tumours were treated and 107 tumours were left untreated. Methods: Skin biopsy sample...
The safety and efficacy of neuromodulation using percutaneous electrical nerve stimulation for the management of trigeminal-mediated headshaking in 168 horses. Early results from the use of neuromodulation by percutaneous electrical nerve stimulation for the management of trigeminal-mediated headshaking in horses were promising but lacked sufficient case numbers and long-term follow-up. The neuromodulatory procedure has since been established as EquiPENS™. Objective: The aim of this study was to report long-term results from a larger number of cases and to investigate for predictors of outcome. Methods: Prospective case series using international, multi-centre data. Methods: Eligible cases were horses with a veterinary diagnosis of trigeminal-media...
Long-term outcome in acquired aplastic anemia treated with an intensified dose schedule of horse antilymphocyte globulin in combination with androgens. Aplastic anemia (AA) is a rare hematopoietic stem cell disease, which can be treated with horse antilymphocyte globulin (ALG) for patients not eligible for bone marrow transplantation. ALG gives about 60% overall survival rate (OS) after 5 years, a 30% of persistent complete remission and a 20% early death rate related to failure. ALG has been incriminated in the emergence of 10 to 20% therapy-related AML/MDS (t-AML/MDS) with the usual doses. Questions remain whether higher doses of ALG could improve the response and OS rates and whether the combination with androgens is able to protect patien...
